Testüberschrift

Medical University of Warsaw is the leading our content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Andrzej Kutner

Principal Investigator (Leader Work Package 6)

Priv.-Doz. Mag. Dr. Martin Schepelmann (Coordinator)

Institute of Pathophysiology and Allergy Research

The Medical University of Vienna is one of the world’s leading medical universities, and hosts Europe’s largest hospital. It is one of the most important centers for postgraduate training and the promotion of young researchers in the international vocational training market. DC-MUV1 will be a member of the Inst. of Pathophysiology and Allergy Research (IPA).

M. Schepelmann, the coordinator of eRaDicate together with Enikö Kallay will supervise DC-MUV1. M. Schepelmann is a specialist in pathophysiology, molecular biology, medicinal chemistry, microscopy, and vascular biology. He was a Marie Curie ESR in the FP7-ITN “Multifaceted CaSR”. Enikö Kallay is specialist in molecular biology of cancer, pathophysiology, and biochemistry and coordinated two doctoral networks.

Research Project

Nuclear receptors act like switches inside of a cell’s nucleus, turning genes on and off and thus controlling the behavior of the cell. The DC in this project will investigate whether new compounds that attach themselves to a specific type of these nuclear receptors – and thus flick the switch on (agonist) or off (antagonist) – can prevent or delay metastasis of colorectal cancer and ovarian cancer. For this, we will test the effect of the compounds on cells in 2D and 3D culture, and establish an innovative in vivo model system. We will assess the tumours and cancer cells by a combination of molecular biology, big data, and cytometry methods.

Furthermore, we will assess whether the compounds can act in synergy with conventional chemotherapeutics. The DC in this project will learn state-of-the art methods in cancer research and will collaborate closely with DC-TG, DC-USC, DC-UoB, and DC-MUW.